Eplerenone

Eplerenone is a synthetic steroid classified as a selective mineralocorticoid receptor antagonist, and it is sometimes described as a selective aldosterone blocker ^[3][5]. Chemically it belongs to the spirolactone family and is closely related to the older drug spironolactone, from which it was derived; its molecular formula is C24H30O6 ^[5]. The molecule was engineered to block aldosterone at its receptor while interacting only weakly with the androgen, progesterone, and glucocorticoid receptors, a selectivity that sets it apart from earlier agents and helps limit hormone-related side effects ^[3][5].

In clinical practice eplerenone is used to treat essential hypertension and to improve outcomes in specific forms of heart failure ^[3][4]. Two large randomized trials established its cardiac role. The EPHESUS study reported that adding eplerenone to standard therapy reduced the risk of death and hospitalization in patients who had left ventricular dysfunction and heart failure after a myocardial infarction ^[1]. The later EMPHASIS-HF trial found comparable reductions in mortality and hospitalization among patients with chronic systolic heart failure and only mild symptoms ^[2]. A Cochrane systematic review concluded that eplerenone meaningfully lowers both systolic and diastolic blood pressure in primary hypertension, although evidence on its effect on long-term morbidity and mortality in that setting remains limited ^[4]. The drug has additionally been studied for central serous chorioretinopathy, an eye disorder, with mixed findings ^[5].

The compound was patented in the early 1980s and approved by the United States Food and Drug Administration in 2002 ^[5]. It has since been authorized in Canada, the European Union, Japan, and other regions ^[5]. Originally brought to market by Pharmacia and later handled by Pfizer, it is sold under the trade name Inspra and, following the expiry of its patent protection, as lower-cost generic formulations ^[5].

Eplerenone is a prescription-only medicine taken by mouth as a tablet ^[5]. Compared with spironolactone, its closest relative, it has a somewhat lower affinity for the mineralocorticoid receptor but a cleaner tolerability profile, producing fewer hormone-linked effects such as breast enlargement in men and sexual dysfunction ^[3]. Because blocking aldosterone tends to raise blood potassium, treatment is accompanied by periodic monitoring, and combining the drug with strong inhibitors of the liver enzyme CYP3A4 is avoided ^[3][5].

Eplerenone is a mineralocorticoid receptor antagonist whose most important risk is hyperkalemia, potentially dangerous elevations in blood potassium, especially in those with kidney impairment or diabetes or taking ACE inhibitors, ARBs, potassium supplements, or other potassium-sparing agents. It can also cause dizziness, low blood pressure, and rises in creatinine, and it interacts with strong CYP3A4 inhibitors. Periodic monitoring of potassium and kidney function is important during use.

Eplerenone causes a significant pharmacodynamic interaction with ACE inhibitors and angiotensin receptor blockers, as all three drug classes increase serum potassium by different mechanisms; when combined, this substantially elevates the risk of dangerous hyperkalemia. Careful monitoring of serum potassium and renal function is essential whenever eplerenone is added to RAAS blockers. In patients with heart failure and mild symptoms, aspirin does not materially reduce the benefits of eplerenone therapy ^[24]. Patients on eplerenone who have reduced kidney function or are over 75 years old face particularly high hyperkalemia risk, and NSAIDs should be avoided or used with caution in this population.

Checking a whole stack? Run it through interactions + stacks.

Eplerenone is a selective aldosterone receptor antagonist of the spirolactone family, developed to retain the cardiovascular benefits of the older drug spironolactone while shedding its troublesome hormonal side effects. It was advanced through development by Searle and Pharmacia and later Pfizer, and received United States Food and Drug Administration approval in 2002, reaching the market as Inspra.

The molecule was designed to bind the mineralocorticoid receptor with high selectivity, interacting only weakly with androgen, progesterone, and glucocorticoid receptors, which is why it largely avoids the breast tenderness and gynecomastia that can accompany spironolactone. Its cardiovascular reputation was built on two major trials: EPHESUS, which studied patients after heart attack complicated by heart failure, and EMPHASIS-HF, published in 2011, which examined patients with systolic heart failure and mild symptoms. Both demonstrated meaningful reductions in death and hospitalization, establishing eplerenone as an important tool in heart failure care.

Eplerenone enjoys a solid reputation as a targeted, well-tolerated way to harness the proven benefits of aldosterone blockade in heart disease. Its principal appeal over spironolactone is selectivity; by leaving the sex-hormone receptors largely alone, it spares patients the antiandrogenic effects that lead some to abandon the older drug. The EMPHASIS-HF trial, which was stopped early because the benefit was so clear, is frequently highlighted as evidence that it reduces both mortality and hospitalization even in patients with only mild symptoms.

It is used both to lower blood pressure and, more importantly, to improve survival in specific forms of heart failure, giving it a valued place in guideline-directed therapy. Candor requires noting that, like all drugs in its class, it can raise potassium to dangerous levels, so periodic monitoring of potassium and kidney function is essential, a modest requirement for a medicine with such a strong outcome pedigree.